Article révisé par les pairs
Résumé : Background: The SADAL study evaluated oral selinexor in patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL) after at least 2 prior lines of systemic therapy. In this post-hoc analysis, we analyzed the outcomes of the SADAL study by DLBCL subtype to determine the effects of DLBCL subtypes on efficacy and tolerability of selinexor. Patients and Methods: Data from 134 patients in SADAL were analyzed by DLBCL subtypes for overall response rate (ORR), overall survival (OS), duration of treatment response, progression-free survival, and adverse events rate. Results: ORR in the entire cohort was 29.1%, and similar in patients with germinal center (GCB) versus non-GCB DLBCL (31.7% vs. 24.2%, P = 0.45); transformed DLBCL showed a trend towards higher ORR than de novo DLBCL: 38.7% vs. 26.2% (P = 0.23). Despite similar prior treatment regimens and baseline characteristics, patients with DLBCL and normal C-MYC/BCL-2 protein expression levels had a significantly higher ORR (46.2% vs.14.8%, P = 0.012) and significantly longer OS (medians 13.7 vs. 5.1 months, hazard ratio 0.43 [95% CI, 0.23-0.77], P = 0.004) as compared with those whose DLBCL had C-MYC and BCL-2 overexpression. Among patients who had normal expression levels of either C-MYC or BCL-2 and baseline hemoglobin levels ≥ 10g/dL, ORR was 51.5% (n = 47), with median OS of 15.5 months and median PFS of 4.6 months. Similar rates of adverse events were noted in all subgroups. Conclusions: Overall, single agent oral selinexor showed strong responses in patients with limited treatment alternatives regardless of germinal center B-cell type or disease origin.

Documents en relation

DI-fusion

  • Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study
    par Schuster, Michael , Zijlstra, Josée J.M. , Casasnovas, René Olivier , Vermaat, Joost J.S.P. , Kalakonda, Nagesh , Goy, Andre , Choquet, Sylvain , Neste, Eric Van Den , Hill, Brian , Thieblemont, Catherine , Cavallo, Federica , De la Cruz, Fátima , Kuruvilla, John , Hamad, Nada , Jäger, Ulrich , Caimi, Paolo , Gurion, Ronit , Warzocha, Krzysztof , Bakhshi, Sameer , Sancho, Juan Manuel , Follows, George , Egyed, Miklos , Offner, Fritz , Vassilakopoulos, Theodoros , Samal, Priyanka , Ku, Matthew , Ma, Xiwen , Corona, Kelly , Chamoun, Kamal , Shah, Jatin , Shacham, Sharon , Kauffman, Michael , Canales, Miguel , Maerevoet, Marie
    Publication 2022
  • Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
    par Maerevoet, Marie , Zijlstra, Josée J.M. , Follows, George , Casasnovas, René Olivier , Vermaat, Joost J.S.P. , Kalakonda, Nagesh , Goy, Andre , Choquet, Sylvain , Van Den Neste, Eric , Hill, Brian , Thieblemont, Catherine , Cavallo, Federica , De la Cruz, Fátima , Kuruvilla, John , Hamad, Nada , Jaeger, Ulrich , Caimi, Paolo , Gurion, Ronit , Warzocha, Krzysztof , Bakhshi, Sameer , Sancho, Juan Manuel , Schuster, Michael , Egyed, Miklos , Offner, Fritz , Vassilakopoulos, Theodoros , Samal, Priyanka , Ku, Matthew , Ma, Xiwen , Corona, Kelly , Chamoun, Kamal , Shah, Jatin , Shacham, Sharon , Kauffman, Michael , Canales, Miguel
    Publication 2021-12
  • The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study
    par Zijlstra, Josée J.M. , Follows, George , Casasnovas, René Olivier , Vermaat, Joost J.S.P. , Kalakonda, Nagesh , Choquet, Sylvain , Hill, Brian , Thieblemont, Catherine , Cavallo, Federica , De la Cruz, Fátima , Kuruvilla, John , Hamad, Nada , Jäger, Ulrich , Caimi, Paolo , Gurion, Ronit , Warzocha, Krzysztof , Bakhshi, Sameer , Sancho, Juan Manuel , Schuster, Michael , Egyed, Miklos , Offner, Fritz , Vassilakopoulos, Theodoros , Samal, Priyanka , Ku, Matthew , Xu, Jenny , Corona, Kelly , Chamoun, Kamal , Shah, Jatin , Canales, Miguel , Maerevoet, Marie
    Publication 2022-02
  • Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma
    par Shah, Jatin , Shacham, Sharon , Kauffman, Michael , Daniele, Patrick , Tomaras, Dimitrios , Tremblay, Gabriel , Casasnovas, René Olivier , Maerevoet, Marie , Zijlstra, Josée J.M. , Follows, George , P Vermaat, Joost J.S. , Kalakonda, Nagesh , Goy, Andre , Choquet, Sylvain , Den Neste, Eric Van , Hill, Brian , Thieblemont, Catherine , Cavallo, Federica , La Cruz, Fátima De , Kuruvilla, John , Hamad, Nada , Bouabdallah, Reda , Jäger, Ulrich , Caimi, Paolo , Gurion, Ronit , Warzocha, Krzysztof , Bakhshi, Sameer , Sancho, Juan Manuel , Schuster, Michael , Egyed, Miklos , Offner, Fritz , Vasilakopoulos, Theodoros T.P. , Samal, Priyanka , Nagy, Agnes , Ku, Matthew , Canales Albendea, Miguel Ángel
    Publication 2021-04
  • Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
    par Kalakonda, Nagesh , Maerevoet, Marie , Cavallo, Federica , Follows, George , Goy, Andre , Vermaat, Joost J.S.P. , Casasnovas, Olivier , Hamad, Nada , Zijlstra, Josée J.M. , Bakhshi, Sameer , Bouabdallah, Reda , Choquet, Sylvain , Gurion, Ronit , Hill, Brian , Jaeger, Ulrich , Sancho, Juan Manuel , Schuster, Michael , Thieblemont, Catherine , De la Cruz, Fátima , Egyed, Miklos , Mishra, Sourav , Offner, Fritz , Vassilakopoulos, Theodoros , Warzocha, Krzysztof , McCarthy, Daniel , Ma, Xiwen , Corona, Kelly , Saint-Martin, Jean-Richard , Chang, Hua , Landesman, Yosef , Joshi, Anita , Wang, Hongwei , Shah, Jatin , Shacham, Sharon , Kauffman, Michael , Van Den Neste, Eric , Canales, Miguel Ángel M.A.
    Publication 2020-07